EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral Immunization with Escherichia coli Nissle 1917 Expressing SARS-CoV-2 Spike Protein Induces Mucosal and Systemic Antibody Responses in Mice

Giovanni Sarnelli iD, Alessandro Del Re, Marcella Pesce iD, Jie Lu iD, Giovanni Esposito, Walter Sanseverino iD, Chiara Corpetti, Silvia Basili Franzin, Luisa Seguella iD, Irene Palenca iD, Sara Rurgo, Fatima Domenica Elisa De Palma iD und 2 weitere

Biomolecules · 21.03.2023 · 13 (3) · 569

DOI: 10.3390/biom13030569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 21.03.2023. Verfasst von Giovanni Sarnelli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Section of Gastroenterology, University Federico II, 80138 Naples, Italy. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As of October 2022, the COVID-19 pandemic continues to pose a major public health conundrum, with increased rates of symptomatic infections in vaccinated individuals. An ideal vaccine candidate for the prevention of outbreaks should be rapidly scalable, easy to administer, and able to elicit a potent mucosal immunity. Towards this aim, we proposed an engineered Escherichia coli (E. coli) Nissle 1917 (EcN) strain with SARS-CoV-2 spike protein (SP)-coding plasmid, which was able to expose SP on its cellular surface by a hybridization with the adhesin involved in diffuse adherence 1 (AIDA1). In this study, we presented the effectiveness of a 16-week intragastrically administered, engineered EcN in producing specific systemic and mucosal immunoglobulins against SARS-CoV-2 SP in mice. We observed a time-dependent increase in anti-SARS-CoV-2 SP IgG antibodies in the sera at week 4, with a titre that more than doubled by week 12 and a stable circulating titre by week 16 (+309% and +325% vs. control; both p < 0.001). A parallel rise in mucosal IgA antibody titre in stools, measured via intestinal and bronchoalveolar lavage fluids of the treated mice, reached a plateau by week 12 and until the end of the immunization protocol (+300, +47, and +150%, at week 16; all p < 0.001 vs. controls). If confirmed in animal models of infection, our data indicated that the engineered EcN may be a potential candidate as an oral vaccine against COVID-19. It is safe, inexpensive, and, most importantly, able to stimulate the production of both systemic and mucosal anti-SARS-CoV-2 spike-protein antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusCOVID-19HumansAnimalsMiceEscherichia coliCOVID-19 VaccinesAntibody FormationPandemicsSARS-CoV-2ImmunizationAntibodies, Viral

Stichwörter der Autor:innen

COVID-19IgAengineered probioticsoral vaccine

Substanzen

spike protein, SARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19 VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Clinical Medicine and Surgery, Section of Gastroenterology, University Federico II, 80138 Naples, Italy.
  • Nextbiomics S.R.L. (Società a Responsabilità Limitata), 80100 Naples, Italy.
  • Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, 00185 Rome, Italy.
  • Department of Anatomy and Cell Biology, China Medical University, Shenyang 110122, China.
  • Department of Molecular Medicine and Medical Biotechnologies, Centro Ingegneria Genetica-Biotecnologie Avanzate s.c.a rl, 80131 Naples, Italy.

ORCID-Profile: Giovanni Sarnelli, Marcella Pesce, Jie Lu, Walter Sanseverino, Luisa Seguella, Irene Palenca, Fatima Domenica Elisa De Palma, Giuseppe Esposito

Zitieren

APA

Sarnelli, G., Del Re, A., Pesce, M., Lu, J., Esposito, G., Sanseverino, W., Corpetti, C., Basili Franzin, S., Seguella, L., Palenca, I., Rurgo, S., De Palma, F. D. E., Zilli, A., & Esposito, G. (2023). Oral Immunization with Escherichia coli Nissle 1917 Expressing SARS-CoV-2 Spike Protein Induces Mucosal and Systemic Antibody Responses in Mice. Biomolecules, 13(3), 569. https://doi.org/10.3390/biom13030569

Vancouver

Sarnelli G, Del Re A, Pesce M, Lu J, Esposito G, Sanseverino W, et al. Oral Immunization with Escherichia coli Nissle 1917 Expressing SARS-CoV-2 Spike Protein Induces Mucosal and Systemic Antibody Responses in Mice. Biomolecules. 2023;13(3):569. doi:10.3390/biom13030569

BibTeX
@article{Sarnelli2023,
  author = {Sarnelli, Giovanni and Del Re, Alessandro and Pesce, Marcella and Lu, Jie and Esposito, Giovanni and Sanseverino, Walter and Corpetti, Chiara and Basili Franzin, Silvia and Seguella, Luisa and Palenca, Irene and Rurgo, Sara and De Palma, Fatima Domenica Elisa and Zilli, Aurora and Esposito, Giuseppe},
  title = {Oral Immunization with Escherichia coli Nissle 1917 Expressing SARS-CoV-2 Spike Protein Induces Mucosal and Systemic Antibody Responses in Mice},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {569},
  doi = {10.3390/biom13030569}
}
Kostenlos starten →